3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Pituitary Neoplasms
4
Nelson Syndrome
2
Multiple Myeloma
2
Carcinoma, Hepatocellular
2
Carcinoid Tumor
2
ACTH Syndrome, Ectopic
2
Uveal Melanoma
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Prolactin-Producing Pituitary Tumor
1
Primary Inoperable Thymoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pituitary ACTH Hypersecretion
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Meningioma
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Insulinoma
1
Hyperinsulinism
1
Interventions
Doxorubicin
4
Gemcitabine
3
pembrolizumab
2
pazopanib
2
fludarabine
2
cixutumumab
2
brostallicin
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Docetaxel
2
Cyclophosphamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
tazemetostat
1
sotigalimab
1
soblidotin
1
romidepsin
1
reolysin
1
perifosine
1
pasireotide
1
lorvotuzumab mertansine
1
ixabepilone
1
interferon gamma-1b
1
exatecan
1
durvalumab
1
drozitumab
1
atezolizumab
1
Trastuzumab
1
Trabectedin
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma, Synovial
×
pasireotide
×
Clear all
NCT06456359
2025-01-13
PAMSARC
University Hospital Heidelberg
Phase 2
Recruiting
28 enrolled